Ranibizumab for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO)

Medical Services Advisory Committee
Record ID 32015000423
English
Authors' objectives: This service is for use of optical coherence tomography in the diagnosis and monitoring of treatment with ranibizumab in patients with retinal vein occlusion. RVO is the second most sight-threatening retinal vascular disease after diabetic retinopathy. If untreated, RVO does not resolve in the majority of patients but results in visual impairment and significant ocular complications. RVO is not a chronic condition; it is an acute event that causes reduced retinal perfusion, retinal ischaemia and increased production of vascular endothelial growth factor (VEGF). Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A (VEGF-A) and is considered a treatment option.
Details
Project Status: Completed
URL for project: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1350-public
Year Published: 2015
URL for published report: http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1350-public
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Australia
MeSH Terms
  • Tomography, Optical Coherence
  • Macular Edema
  • Retinal Vein Occlusion
  • Antibodies, Monoclonal, Humanized
  • Angiogenesis Inhibitors
  • Ranibizumab
  • Visual Acuity
Contact
Organisation Name: Medical Services Advisory Committee
Contact Address: MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name: msac.secretariat@health.gov.au
Contact Email: msac.secretariat@health.gov.au
Copyright: Medical Services Advisory Committee (MSAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.